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Guidelines for developmental toxicity studies require that the highest dose(s) should induce some signs
of maternal toxicity. However, the interpretation of the results is often difﬁcult when developmentally
toxic effects are recorded only at maternotoxic doses, as it is impossible to ascertain whether the devel-
opmental effects are maternally mediated or not. In order to avoid this source of misinterpretation we
suggest to use in developmental toxicity tests for environmental chemicals the maximum dose unable
to produce maternal toxic effects extrapolated by previous short term toxicity studies.
 2011 Elsevier Inc. All rights reserved.Guidelines for developmental toxicity studies require the admin-
istration of doses able to induce clear signs of maternal toxicity. The
OECD test No. 414 (2001) indicates that ‘‘the highest dose should be
chosenwith the aim to induce somedevelopmental and/ormaternal
toxicity (clinical signs or a decrease in bodyweight), but not death or
severe suffering’’. This indication is a continuous source of problems
either in the conduct of the experiments and in the interpretation of
the results. The choice of a dose which is able to produce clear signs
of toxicity without being lethal for some animals or inducing severe
suffering (what is the limit of a severe suffering?) is rather difﬁcult.
As a consequence it is frequent to observe experimentswith very se-
vere toxic effects at the highest dose, including death or dramatic
reduction of body weight. During our long term experience, serving
as member of the Committee for Control and Registration of Pesti-
cides of Italian Ministry of Public Health, we had the opportunity
to examine some hundred of reports on developmental toxicity of
pesticides. Although in51/91of acceptable reports theonly reported
sign of maternal toxicity was a reduction of maternal weight gain
(10–20% of the control value), in 28/91 reports maternal toxicity in-
cluded sedation, loss of weight, immobility, piloerection, arched
posture, chromodacryorrhea, chromorhinorrhea, ataxia, alopecia,
hyperactivity, lethargy, hypersalivation, blood around the mouth,
blood around vagina, diarrhea, gastric lesions. In particular in rab-
bits, death, sacriﬁce in extremis, abortion, reduced bodyweightwere
very frequent reported ﬁndings (in 58/91 reports). In some cases the
frequency of maternal death and abortion was so high to preclude
the evaluation of the study with the consequence of repeating the
study using lower doses. Furthermore, the ﬁnding of malformations
concomitant with maternal toxicity sometimes induced to perform
further experiments in order to clarify the results with consequent
waste of money, time, and animals. It must be stressed, accordingll rights reserved.
i).with our data base on pesticides, that maternal toxicity may be re-
lated to a range of effects. Severe maternotoxic effects in rat studies
(reducedbodyweight gain >20%, clinical signs)were correlatedwith
39% cases of increased resorptions, 53% of reduced fetal weight, 25%
of increased frequency of minor anomalies, 17% of increased fre-
quency of malformations, and 11% of no effects. On the contrary, a
moderatematernal toxicity (10–20% reducedmaternalweight gain)
were correlated with 5% cases of increased resorptions, 49% of re-
duced fetal weight, 23% of increased frequency of minor anomalies,
37% no effects, only 2% of increasedmalformations. These data seem
to suggest a correlation between the severity of maternal toxicity
and the effects on the conceptuses, however a deﬁnite relationship
cannot be extrapolated because the concurrent role of the test com-
pound in inducing the effectsmust be taken into account. The role of
maternal toxicity in the induction of adverse effects on conceptuses
is a very long standing problem that has been faced by a number of
researchers (Chahoud et al., 1999; Chernoff et al., 1989; ECETOC,
2004; Kavlock et al., 1985; Khera, 1984, 1985; Paumgartten, 2010;
Rogers et al., 2005), apparently without a deﬁnite solution. First of
all the deﬁnition of maternal toxicity is very poor. The guidelines
are not explicative on this point, limiting to say ‘‘clinical signs or a
decrease in body weight’’. The clinical signs indicative of maternal
toxicity are numerous: from the reduced bodyweight gain to severe
behavioral or morphological alterations. What are these symptoms
expression of (pain, toxicity at the level of speciﬁc organs, altered
homeostasis) is difﬁcult to be determined. As a consequence, it is
impossible to evaluate if the observed maternal symptoms have
any effect on the conceptus. Moreover, in the case of developmental
toxicity at maternotoxic dose levels it is impossible to discriminate
between direct and maternotoxicity mediated effects.
The problem is a major concern if related to the decision of
the European Commission (1992) to introduce a system for
classiﬁcation and labeling of chemicals. The chemicals classiﬁed
as dangerous for development are divided into three categories.
Table 1
Ratio between the highest dose used in some developmental toxicity studies on rat to
test pesticides and the admissible daily intake.
Pesticide Highest dose in rat mg/kgbw ADI mg/kgbw Ratio
Triadimefon 100 0.01 10,000
Tebuconazole 120 0.03 4000
Cyromazine 600 0.02 30,000
Teﬂubenzuron 250 0.01 25,000
Penconazole 300 0.03 10,000
Endosulfan 6 0.006 1000
Diazinon 100 0.0002 500,000
Imazalil 40 0.01 4000
Metiram 160 0.03 5300
Myclobutanil 460 0.03 15,300
Amitraz 12 0.003 4000
Clofentezine 3200 0.02 160,000
Buprofezin 800 0.01 80,000
Cycloxydim 800 0.07 11,400
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cal) data indicating that ‘‘there is sufﬁcient evidence to establish
a causal relationship between human exposure to the substance
and subsequent developmental effect’’. Allocation in Cat. 2 or 3 is
based on animal studies. In both cases it is stressed that the ad-
verse effects on conceptus must be obtained ‘‘in appropriate ani-
mal studies in absence of signs of marked maternal toxicity, or at
around the same dose levels as other toxic effects but which are
not a secondary non-speciﬁc consequence of the other toxic ef-
fects’’. This classiﬁcation has a strong impact on the chemical mar-
keting because the chemicals that are classiﬁed must carry risk
phrases such as ‘‘possible risk of harm to the unborn child’’ that
may have serious consequences on their marketing. Furthermore,
in some countries (e.g. in Brazil) registration of any pesticide that
was found to be teratogenic is forbidden (Paumgartten, 2010).
The difference between Cat. 2 and 3 is that the results must pro-
vide strong evidence of adverse developmental effects (Cat. 2) or
some evidence of adverse developmental effects but insufﬁcient
to place the chemicals in Cat. 2. It is quite evident that this classi-
ﬁcation system is a source of continuous conﬂicts between regula-
tory agencies and manufacturers. The regulatory agencies, in order
to safeguard the human health, tend to classify in Cat. 2 or 3 all
chemicals able to produce signs of adverse developmental effects
even in presence of maternal toxicity considering the adverse
developmental effects as an intrinsic property of the test com-
pound, not mediated by maternal toxicity. On the contrary the
manufacturer position is that some adverse developmental effects
(reduced fetal weight, increase of minor anomalies or variations,
increase of resorptions) could be mediated by maternal toxicity
and not a direct effect of the test compound on the conceptus.
During the ECETOCWorkshop on maternal toxicity (2004) it has
been proposed, in order to better deﬁne the maternal effects, to in-
crease the information about maternal parameters (e.g. acute
phase proteins in serum, serum Zn concentrations, haematology,
clinical chemistry, organ weight, and histopathology). The collec-
tion of these additional information would signiﬁcantly increase
the cost of the studies without deﬁnitely solving the problem
and producing, on the contrary, some additional questions, for
example, at what time of gestation to collect these data: during
the middle of organogenetic period or at termination of treatment?
As the more recent guidelines (OECD, 2001) for industrial or agri-
cultural chemicals suggest to continue the treatment ‘‘to the day
prior to scheduled caesarian section’’, the maternotoxic manifesta-
tion observed at the end of treatment may be different from those
observed at midgestation, the period of highest susceptibility for
embryotoxic effects. The paper by Beyer et al. (2010) summarizes
the discussions of workshops on maternal toxicity held during
the Society of Toxicology, Teratology Society, and European Tera-
tology Society meetings in 2009. The majority of the presentation
stressed the reduced maternal weight gain or reduced maternal
weight as main signs of maternal toxicity and correlated this signs
of toxicity with reduced food intake with possible indirect conse-
quences on fetal weight or other developmental effects. Like in sev-
eral other papers/workshops a consensus was not obtained about
the relationship between maternal and fetal effects. Some partici-
pants agreed that maternal toxicity can provide an explanation
for some developmental effects. In this case the regulatory author-
ities would not label test compounds as developmental toxicants.
But this assertion must be accepted on the basis of supporting data,
e.g. mechanistic data provided by the manufacturers on the basis
of ad hoc studies. That means a lot of time and a lot of animals to
be used, without a certainty of success. On the other hand, some
regulators did not agree with this position, arguing that embryof-
etal ﬁndings are important regardless of any relationship to mater-
nal toxicity, in particular when the NOEL of the test article is
decreased based on developmental toxicity data.The use of a dose level with the speciﬁc aim to induce maternal
toxicity, i.e. some degree of animal suffering, is also against the
ethical concepts and the Directive 2010/63/EU of the European Par-
liament on the protection of animals used for scientiﬁc purposes
which at the art. 13 (Choice of methods), §2 says ‘‘choose between
procedures those which meet the following requirements: c) cause
the least pain, suffering, distress or lasting harm’’. In our opinion
the use of maternally toxic doses is just confounding without a sig-
niﬁcant improvement of the method. If the use of maternotoxic
doses may make sense in testing pharmaceuticals, as the distance
between the therapeutic and toxic doses can be short, in the case of
environmental chemicals the exposure of pregnant women, in nor-
mal conditions excluding disasters, is at maximum the ADI that in
general is a very small dose, ﬁxed at a hundredth or less of the
NOEL from long term or developmental toxicity studies. As re-
ported in Table 1, the ratio between the highest dose used in devel-
opmental toxicity studies and the ADI is among 1000–500,000. As a
consequence the use of excessively high doses in order to obtain
maternal toxicity is not necessary in relation to the extrapolation
to human exposure. On this purpose, the results of the EU coordi-
nated programme on pesticide residues in food available to Euro-
pean consumers are relevant. A total of 11,610 samples of
different vegetables and fruits from 27 member states were ana-
lyzed for 78 pesticides. In 62.1% of samples no residues were de-
tected; in 35.7% of samples the residues were below the MRL
(Maximum Residue Levels), and only 2.2% of samples exceeded
the MRL (EFSA, 2008). This is a reassuring result. Although the
MRL for agricultural pesticides is derived from trials performed
according to good agricultural practice rather than the health-
based exposure limit of ADI, a strict correlation does exist between
MRL and ADI because a proposed MRL would not be approved un-
less the estimated intakes based on that MRL were consistent with
exposure below the ADI (Renwick, 2002). Also the workers may be
protected without using maternotoxic doses. The AOEL (Admissi-
ble Operator Exposure Level) is deﬁned as the maximum amount
of active substance to which the operator may be exposed without
any adverse health effects and is obtained from toxicological data-
base in a manner similar to ADI. In some cases the compulsory use
of particular personal protective equipment is also requested.
According to the current EU legislation, the AOEL set for operators
and workers should be also applicable to bystanders (persons in
vicinity of a pesticide application).
Two recent papers, signed also by scientists working in US regu-
latory agencies, agreewith the hypothesis of avoidingmaternotoxic
doses and suggest new directions in study designs and testing strat-
egies: ‘‘for industrial and agricultural compounds found in the
environment, typical human exposures tend to occur atmuch lower
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animals.Omissis. Nonetheless, most testing guidelines for chemicals
still specify gavage administration of maximally tolerated dose lev-
els as the default, even in caseswherehumanexposure are known to
beorders ofmagnitude lower.Omissis. Thenegative consequencesof
this practice include unnecessary animal use, cost, and effort as the
irrelevant ﬁndings generated are further investigated. This testing
scheme also can lead to the erroneous classiﬁcation and labeling
of compounds which pose little risk to humans’’ (Carney et al.,
2011). The second paper (Brannen et al., 2011) is a summary of the
discussion of a workshop on developmental toxicology – new direc-
tions, held by ILSI and HESI. In the chapter ‘‘Dose selection’’ is re-
ported: ‘‘there were comments throughout the discussion about
the need to move away from high, maternally toxic doses that may
be meaningless for human exposure. For industrial chemicals, an
alternative approach gaining some traction is the setting of the high
dose level based on toxicokinetics, speciﬁcally to avoid dose levels
which saturate metabolic and excretory processes and result in
non linear kinetics. Omissis. It was the consensus of the majority of
attendees that a more rational upper limit should be adopted’’.
Actually, another relevant point should be addressed: the dose-
dependent transitions. A transition is a change with increasing
dose in key underlying kinetic and/or dynamic factors that inﬂu-
ence the mechanism responsible for the observed toxicity, result-
ing in a change in the relationship of the response rate as
function of dose (Slikker et al., 2004a). The saturable or inducible
factors such as absorption, distribution, elimination, metabolism,
besides receptor interactions and altered homeostasis are the basis
for dose-dependent transitions. When very high doses are used in
toxicity tests, it is likely to be in the range of dose-dependent tran-
sitions, obtaining data useless for risk assessment. Just one exam-
ple related to developmental toxicity reported by Slikker et al.
(2004b): high doses of ethylene glycol (EG, >1000 mg/kg) resulted
in congenital malformations in rodents. Further in vivo and in vitro
studies established that the congenital malformations were due to
a metabolite of EG, glyoxylic acid (GA). The pharmacokinetics of EG
showed the primary importance of a dose-dependent transition
involving saturation of GA oxidation leading to accumulation of
this toxic metabolite at high dose levels.
In conclusion, the use of maternotoxic doses in developmental
toxicity studies of environmental chemical is not to be recom-
mended for different reasons: (1) may produce results difﬁcult to
be interpreted and source of continuous discussions between
sponsors and regulatory agency often resulting in additional but
not conclusive experiments; (2) may lead to a misclassiﬁcation of
chemicals; (3) the doses are thousand times the ADIs; (4) the ob-
tained results may be misleading because of dose-dependent
transitions.
On the basis of what exposed above, the only way to bypass the
problem of maternal toxicity and its pernicious inﬂuence on the
interpretation of developmental toxicity studies, is to avoid the
use of maternotoxic doses in such kind of studies when performed
on environmental chemicals. In order to avoid this source of misin-
terpretation we suggest that the currently used maximumtolerated dose be replaced with new, more reﬁned criteria for dose
level selection. The highest dose should be a dose sufﬁciently high
but unable to induce overt clinical signs of toxicity or reduction of
maternal body weight gain. We suggest that the highest dose may
be chosen on the basis of previous short term toxicity studies and
on the basis of a range ﬁnding developmental toxicity study per-
formed in a range of doses, for example, between the mid and
the highest tested doses in a 28-day general toxicity study. If the
test compound has an embryotoxic potency, this dose will produce
more clear developmental effects without interferences of mater-
nal toxicity avoiding the difﬁculties of data interpretation when
the developmental effects are observed at maternally toxic dose
levels and will be in any case sufﬁciently higher than the ADI for
the safety of the human conceptuses.
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